Martin Reck
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 288
- Lung Cancer Research Studies 135
- Cancer Immunotherapy and Biomarkers 110
- Colorectal Cancer Treatments and Studies 50
- Peptidase Inhibition and Analysis 40
-
- Lung Cancer Treatments and Mutations 206
- Lung Cancer Diagnosis and Treatment 52
- Co-authors
- Julie R. Brahmer (29 shared papers)Delvys Rodríguez‐Abreu (37 shared papers)Rina Hui (23 shared papers)Nir Peled (22 shared papers)Maya Gottfried (18 shared papers)Tibor Csőszi (13 shared papers)Andrew Robinson (11 shared papers)Ali Tafreshi (11 shared papers)
- Journals
- Journal of Clinical Oncology (110 papers)Annals of Oncology (104 papers)Journal of Thoracic Oncology (42 papers)Lung Cancer (23 papers)Cancer Research (11 papers)
- Partner nations
- GermanyUnited StatesSpain
In The Last Decade
Martin Reck
385 papers receiving 23.1k citations
Martin Reck's Hit Papers
Peers
Comparison fields: 5 of 139
- Oncology 14.0k
- Pulmonary and Respiratory Medicine 9.6k
- Cancer Research 2.3k
- Immunology 2.1k
- Molecular Biology 3.6k
Countries citing papers authored by Martin Reck
This map shows the geographic impact of Martin Reck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Reck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Reck more than expected).
Fields of papers citing papers by Martin Reck
This network shows the impact of papers produced by Martin Reck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Reck. The network helps show where Martin Reck may publish in the future.
Co-authors
The 25 scholars most cited alongside Martin Reck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 404 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 7183 |
| 2 | Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL Hit paper breakdown → | 2009 | 1183 |
| 3 | Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Hit paper breakdown → | 2019 | 1144 |
| 4 | Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2012 | 794 |
| 5 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Hit paper breakdown → | 2021 | 654 |
| 6 | Management of non-small-cell lung cancer: recent developments Hit paper breakdown → | 2013 | 594 |
| 7 | Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 546 |
| 8 | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) Hit paper breakdown → | 2021 | 520 |
| 9 | Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Hit paper breakdown → | 2010 | 496 |
| 10 | Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Hit paper breakdown → | 2012 | 450 |
| 11 | PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2013 | 440 |
| 12 | Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 401 |
| 13 | 2010 | 365 | |
| 14 | Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Hit paper breakdown → | 2021 | 348 |
| 15 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial Hit paper breakdown → | 2015 | 338 |
| 16 | Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 320 |
| 17 | 2010 | 259 | |
| 18 | 2014 | 237 | |
| 19 | 2019 | 202 | |
| 20 | 2008 | 176 |
About Martin Reck
Martin Reck is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Epidemiology, having authored 404 papers that have together received 23.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (206 papers), Lung Cancer Research Studies (135 papers), Cancer Immunotherapy and Biomarkers (110 papers), Lung Cancer Diagnosis and Treatment (52 papers), Colorectal Cancer Treatments and Studies (50 papers), Cancer Genomics and Diagnostics (48 papers), Peptidase Inhibition and Analysis (40 papers) and Cancer therapeutics and mechanisms (37 papers). The work is most often cited by research in Oncology (14.0k citations), Pulmonary and Respiratory Medicine (9.6k citations), Cancer Research (2.3k citations), Immunology (2.1k citations) and Molecular Biology (3.6k citations). Martin Reck has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Julie R. Brahmer, Delvys Rodríguez‐Abreu, Rina Hui, Nir Peled, Maya Gottfried, Tibor Csőszi, Andrew Robinson, Ali Tafreshi, Suman Rao and Sinéad Cuffe. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.